Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of Tablet Formulations Containing the Anhydrous and Monohydrate (FMI) Forms of MK0431

This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

Inclusion Criteria:

• Subject is in good health
• Female subjects must have a negative pregnancy test
• Subject is within 30% of ideal body weight
• Subject does not smoke
• Subject agrees to follow the study guidelines

Exclusion Criteria:

• Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
• Subject has a history of hypoglycemia
• Subject has a history of any hepatic disease
• Subject is taking any oral, parenteral, topical or implantable contraceptives